A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of ACZONE in
subjects treated with the HER1/EGFR inhibitor Tarceva (erlotinib) who develop a rash on the
face